CSIMarket
 


Elutia Inc   (NASDAQ: ELUT)
Other Ticker:  
 

Elutia Inc 's Quick Ratio

ELUT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

 


Elutia Inc 's Cash & cash equivalent grew by 31.11 % in the Q1 2025 sequentially, while Current Liabilities decreased, this led to improvement in Elutia Inc 's Quick Ratio to 0.55, Quick Ratio remained below Elutia Inc average.

Within Biotechnology & Pharmaceuticals industry 103 other companies have achieved higher Quick Ratio than Elutia Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 1657, from total ranking in the fourth quarter 2024 at 1744.

Explain Quick Ratio?
How much Cash & cash equivalents ELUT´s has?
What are ELUT´s Current Liabilities?


ELUT Quick Ratio (Mar 31 2025)
Q1
(Dec 31 2024)
Q4
(Sep 30 2024)
Q3
(Jun 30 2024)
Q2
(Mar 31 2024)
Q3
Y / Y Current Liabilities Change 0.29 % 9.89 % 6.98 % 15.21 % 7.57 %
Y / Y Cash & cash equivalent Change 38.3 % -31.32 % 77.32 % 95.65 % 6.46 %
Quick Ratio MRQ 0.55 0.4 0.73 0.53 0.4
ELUT's Total Ranking # 1657 # 1744 # 1864 # 1664 # 1617
Seq. Current Liabilities Change -6.12 % -5.34 % 1.93 % 10.72 % 2.86 %
Seq. Cash & cash equivalent Change 31.11 % -48.57 % 41.53 % 44.91 % -34.89 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 104
Healthcare Sector # 572
Overall Market # 1657


Quick Ratio Statistics
High Average Low
1.46 0.66 0.06
(Dec 31 2020)   (Sep 30 2020)




Financial Statements
Elutia Inc 's Current Liabilities $ 31 Millions Visit ELUT's Balance sheet
Elutia Inc 's Cash & cash equivalent $ 17 Millions Visit ELUT's Balance sheet
Source of ELUT's Sales Visit ELUT's Sales by Geography


Cumulative Elutia Inc 's Quick Ratio

ELUT's Quick Ratio for the trailling 12 Months

ELUT Quick Ratio

(Mar 31 2025)
12 Months
(Dec 31 2024)
12 Months
(Sep 30 2024)
12 Months
(Jun 30 2024)
12 Months
(Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 7.99 % 9.86 % 7.34 % 8.8 % 0.95 %
Y / Y Cash & cash equivalent TTM Growth 33.94 % 27.04 % 44.05 % 39.76 % 4.26 %
Quick Ratio TTM 0.55 0.52 0.58 0.5 0.45
Total Ranking TTM # 2541 # 2303 # 3432 # 2840 # 1555
Seq. Current Liabilities TTM Growth 0.07 % 2.28 % 1.78 % 3.66 % 1.8 %
Seq. Cash & cash equivalent TTM Growth 6.89 % -7.97 % 17.39 % 15.98 % 1.39 %


  News about Elutia Inc Quick Ratio

Elutia Inc. Captures Investor Confidence with $13.26 Million Registered Direct Offering for Future Growth

Elutia Inc. Raises Funds through Registered Direct Offering to Fuel Growth
Silver Spring-based company, Elutia Inc., recently announced a registered direct offering that is set to raise approximately $13.26 million for the company. The offering entails the purchase and sale of 3,175,000 shares of Elutia s Class A common stock, priced at $3.40 per share, along with 725,000 prefunded warrants at a purchase price of $3.399 per warrant. The prefunded warrants are exercisable immediately at an exercise price of $0.001 per warrant. Elutia aims to utilize the proceeds to fund various growth initiatives. The offering is anticipated to conclude by June 18, 2024, pending customary closing conditions.
Elutia Inc., a Nasdaq listed company (symbol: ELUT), has secured a definitive agreement with investors for the registered direct offering, signifying a significant milestone for the organization. The offering involves the sale of a considerable number of shares and warrants, presenting a lucrative opportunity for investors to support Elutia s strategic objectives. The purchase price for each share and prefunded warrant reflects the company s market value and the confidence of investors in its future prospects.


On the trailing twelve months basis ELUT Cash & cash equivalent grew by 38.3 % in Q1 2025 year on year, faster than Current Liabilities, this led to increase in in Elutia Inc 's Quick Ratio to 0.55, Quick Ratio remained below ELUT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 120 other companies have achieved higher Quick Ratio than Elutia Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2303 to 2541.

Explain Quick Ratio?
How much Cash & cash equivalents ELUT´s has?
What are ELUT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 121
Healthcare Sector # 704
Within the Market # 2541


trailing twelve months Quick Ratio Statistics
High Average Low
1.23 0.6 0.28
(Sep 30 2021)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Cognition Therapeutics inc   1.50 $ 16.428  Millions$ 10.950  Millions
Adma Biologics Inc  1.37 $ 71.625  Millions$ 52.167  Millions
Sab Biotherapeutics Inc   1.33 $ 12.850  Millions$ 9.653  Millions
Meiragtx Holdings Plc  1.27 $ 66.523  Millions$ 52.372  Millions
C4 Therapeutics Inc   1.26 $ 51.293  Millions$ 40.820  Millions
Immunitybio inc   1.25 $ 61.591  Millions$ 49.205  Millions
Halozyme Therapeutics Inc   1.17 $ 176.328  Millions$ 150.379  Millions
Adaptimmune Therapeutics Plc  1.17 $ 59.563  Millions$ 51.072  Millions
Curis Inc   1.08 $ 20.282  Millions$ 18.816  Millions
Invivyd Inc   0.99 $ 48.078  Millions$ 48.701  Millions
Quince Therapeutics Inc   0.93 $ 7.771  Millions$ 8.356  Millions
Bio techne Corp  0.83 $ 140.670  Millions$ 169.204  Millions
Aptose Biosciences Inc   0.83 $ 4.743  Millions$ 5.714  Millions
Protalix Biotherapeutics inc   0.80 $ 19.458  Millions$ 24.322  Millions
Phoenix Biotech Acquisition Corp  0.66 $ 5.204  Millions$ 7.859  Millions
Elutia Inc   0.55 $ 17.358  Millions$ 31.351  Millions
Sangamo Therapeutics Inc   0.51 $ 25.180  Millions$ 49.562  Millions
Mink Therapeutics Inc   0.46 $ 3.235  Millions$ 7.003  Millions
Amgen Inc   0.38 $ 8,810.000  Millions$ 23,008.000  Millions
Intensity Therapeutics Inc   0.35 $ 0.929  Millions$ 2.629  Millions
Dbv Technologies S a   0.33 $ 12.962  Millions$ 39.593  Millions
Coherus Biosciences inc   0.32 $ 82.411  Millions$ 255.042  Millions
Outlook Therapeutics Inc   0.31 $ 7.556  Millions$ 24.768  Millions
Biocardia Inc  0.29 $ 0.949  Millions$ 3.234  Millions
Atara Biotherapeutics Inc   0.29 $ 13.841  Millions$ 47.892  Millions
Bluebird Bio Inc   0.25 $ 78.744  Millions$ 315.078  Millions
Redwoods Acquisition Corp  0.24 $ 0.566  Millions$ 2.338  Millions
Windtree Therapeutics Inc  0.18 $ 1.173  Millions$ 6.476  Millions
Brainstorm Cell Therapeutics inc   0.15 $ 1.644  Millions$ 10.901  Millions
Vaxart Inc   0.13 $ 13.240  Millions$ 98.504  Millions

Date modified: 2025-05-15T07:40:47+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com